Minoxidil for Alopecia Areata

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Ohio State University Comprehensive Cancer Center, Columbus, OH
Alopecia Areata+25 More
Minoxidil - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This early phase I trial studies the possible benefits and/or side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast cancer. Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced quality of life and early cessation of therapy in women undergoing treatment for breast cancer. Patients on endocrine therapy commonly report hair loss or thinning. Minoxidil is a drug that may promote hair growth and reduce hair loss. Oral minoxidil may increase hair density in women with EIA, and work the same as topical minoxidil in treating EIA in patients with breast cancer.

Eligible Conditions

  • Alopecia Areata
  • Breast
  • Anatomic Stage III Breast Cancer AJCC v8
  • Endocrine Therapy-Induced Alopecia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alopecia Areata

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: At 12 months

At 12 months
CADS score emotional
Patient-reported outcomes
At 3 months
Chemotherapy Alopecia Distress Scale (CADS) score
At 6 months
CADS score physical
Baseline to 12 months
Change in hair density
Up to 12 months
Occurrence of at least one adverse event (AE) of grade 1 or higher
Proportion of days assigned medication was taken/applied

Trial Safety

Safety Progress

1 of 3

Other trials for Alopecia Areata

Trial Design

2 Treatment Groups

Arm I (topical minoxidil)
1 of 2
Arm II (orally minoxidil)
1 of 2
Active Control
Experimental Treatment

50 Total Participants · 2 Treatment Groups

Primary Treatment: Minoxidil · No Placebo Group · Phase < 1

Arm II (orally minoxidil)Experimental Group · 3 Interventions: Quality-of-Life Assessment, Questionnaire Administration, Minoxidil · Intervention Types: Other, Other, Drug
Arm I (topical minoxidil)ActiveComparator Group · 3 Interventions: Quality-of-Life Assessment, Questionnaire Administration, Minoxidil · Intervention Types: Other, Other, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minoxidil
2011
Completed Phase 2
~170

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 12 months
Closest Location: Ohio State University Comprehensive Cancer Center · Columbus, OH
Photo of Columbus 1Photo of Columbus 2Photo of Columbus 3
2011First Recorded Clinical Trial
1 TrialsResearching Alopecia Areata
206 CompletedClinical Trials

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
281 Previous Clinical Trials
285,768 Total Patients Enrolled
Brittany L Dulmage, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Eligibility Criteria

Age 18+ · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.